Download PDF
Planta Med 2006; 72(7): 621-626
DOI: 10.1055/s-2006-931572
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Astragaloside IV Dilates Aortic Vessels from Normal and Spontaneously Hypertensive Rats through Endothelium-Dependent and Endothelium-Independent Ways

Wei-Dong Zhang1 , 4 , Chuan Zhang1 , Xu-Hui Wang2 , Ping-Jin Gao3 , Ding-Liang Zhu3 , Hong Chen2 , Run-Hui Liu1 , Hui-Liang Li1
  • 1Department of Natural Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai, P. R. China
  • 2Department of Pharmacology, School of Medicine, Shanghai Jiao Tong University, Shanghai, P. R. China
  • 3Shanghai Institute of Hypertension, Shanghai, P. R. China
  • 4School of Pharmacy, Shanghai Jiao Tong University, Shanghai, P. R. China
Further Information

Publication History

Received: November 1, 2005

Accepted: January 24, 2006

Publication Date:
29 May 2006 (online)

    Permissions and Reprints

Abstract

The major active constituent of Astragalus membranaceus, astragaloside IV, has been found to have properties of increasing coronary flow and cardioprotection. In this study, we examined the direct effects of astragaloside IV on vessel dilatation and contraction in isolated aortic rings from both normal and stroke-prone spontaneously hypertensive rats (SHR-SP) in vitro. The results demonstrated that astragaloside IV could antagonize vessel contractions induced by phenylephrine and potassium chloride in a concentration-dependent way. Astragaloside IV reduced CaCl2-induced contractions in Ca2+-free solution. Astragaloside IV also dilated aortic vessels in a dose-dependent manner, which was partially endothelium-dependent through the nitric oxide (NO) and cGMP pathways. The aorta from 6-month-old SHR-SP rats showed impaired endothelium function, and astragaloside IV dilated the vessels from the hypertensive rats to a lesser extent as compared with normal control rats. In the presence of perivascular fat tissue, the contractile responses induced by angiotensin II and phenylephrine were also attenuated by astragaloside IV. Collectively, this study provides functional evidence that astragaloside IV exerts vessel dilatation properties through the endothelium-dependent NO-cGMP pathway in normal and hypertensive rats. It blocks extracellular calcium influx and participates in vessel relaxation partly through phenylephrine and angiotensin II inhibition when perivascular fat is present.

Key words

Astragaloside IV - vasodilatation - endothelium - perivascular fat - hypertension

References

  • 1 Zhou J Y, Fan Y, Kong J L, Wu D Z, Hu Z B. Effects of components isolated from Astragalus membranaceus Bunge on cardiac function injured by myocardial ischemia reperfusion in rats.  China J Chin Mater Med. 2000;  25 300-2
    PubMedGoogle Scholar
  • 2 Liu Y X, Liu Z P, Jiao J J. Influence of astragaloside IV on normal and depressed ventricular heart function in rats.  Zhong Cao Yao. 2001;  32 332-4
    PubMedGoogle Scholar
  • 3 Zhou S, Shao W, Wang W. Clinical study of Astragalus injection plus ligustrazine in protecting myocardial ischemia reperfusion injury.  Chin J Integr Trad Western Med. 2000;  20 504-7
    PubMedGoogle Scholar
  • 4 Luo Y, Qin Z, Hong Z, Zhang X, Ding D, Fu J H. et al . Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia.  Neurosci Lett. 2004;  363 218-23
    CrossrefPubMedGoogle Scholar
  • 5 Li Z P, Cao Q. Effects of astragaloside IV on myocardial calcium transport and cardiac function in ischemic rats.  Acta Pharmacol Sin. 2002;  23 898-904
    PubMedGoogle Scholar
  • 6 Zhang W D, Chen H, Zhang C, Li H L, Liu R H, Chen H Z. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro . Planta Med, in press
    Google Scholar
  • 7 Wang H K, He K, Ye J L. Chemical constituents of Astragalus mongholicus .  Zhong Cao Yao. 1987;  18 5-7
    PubMedGoogle Scholar
  • 8 Löhn M, Dubrovaska G, Lauterbach B, Luft F C, Gollasch M, Sharma A M. Periadventitial fat releases a vascular relaxing factor.  FASEB J. 2002;  16 1057-63
    CrossrefPubMedGoogle Scholar
  • 9 Tirapelli C R, Ambrosio S R, da Costa F B, Coutinho S T, de Oliveira D CR, de Oliveira A M. Analysis of the mechanisms underlying the vasorelaxant action of kaurenoic acid in the isolated rat aorta.  Eur J Pharmacol. 2004;  492 233-41
    CrossrefPubMedGoogle Scholar
  • 10 Hudgins A, Weiss G. Effects of Ca2+ removal upon vascular smooth muscle contraction induced by norepinephrine, histamine and potassium.  J Pharmacol Exp Ther. 1968;  159 91-7
    PubMedGoogle Scholar
  • 11 Hirata S, Enoki T, Kitamura R, Vinh V H, Nakamura K, Mori K. Effects of isoflurane on receptor-operated Ca2+ channels in rat aortic smooth muscle.  Brit J Anaesth. 1998;  81 578-83
    PubMedGoogle Scholar
  • 12 Lee C N, Wong K L, Liu J C, Chen Y J, Cheng J T, Chan P. Inhibitory effect of stevioside on calcium influx to produce antihypertension.  Planta Med. 2001;  67 796-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gu Y, Deng D M. Progress in hypertension with Qi-deficiency and blood stasis.  J Tradit Chin Med. 2001;  19 324-6
    PubMedGoogle Scholar
  • 14 Robertson B E, Schubert R, Hescheler J, Nelson M T. cGMP-dependent protein kinase activates Ca2+-activated K+ channels in cerebral artery smooth muscle cells.  Am J Physiol. 1993;  265 C299-303
    PubMedGoogle Scholar
  • 15 Garthwaite J, Southam E, Boulton C L, Nielsen E B, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one.  Mol Pharmacol. 1995;  48 184-8
    PubMedGoogle Scholar
  • 16 Bussemaker E, Popp R, Fisslthaler B, Larson C M, Fleming I, Busse R. et al . Aged spontaneously hypertensive rats exhibit a selective loss of EDHF-mediated relaxation in the renal artery.  Hypertension. 2003;  42 562-8
    CrossrefPubMedGoogle Scholar
  • 17 Ulker S, McMaster D, McKeown P P, Bayraktutan U. Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation.  Cardiovasc Res. 2003;  59 488-500
    CrossrefPubMedGoogle Scholar
  • 18 Luo X P, Shi H M, Zeng Z Y, Fan W H, Dai R H. Effect of Astragalus membranaceus on post-infarction function and remodeling of left ventricle.  Chin J Pathophysiol. 1999;  15 639-42
    PubMedGoogle Scholar
  • 19 Shi G G, Chen J C, Li Z C, Liu X P. Direct effect of Astragalus membranaceus on coronary artery.  Trad Chin Drug Res Clin Pharmacol. 1999;  10 38-9
    PubMedGoogle Scholar
  • 20 Zhang B Q, Sun J, Hu S J, Shan Q X, Xia Q. Astragalus membranaceus induced endothelium-dependent vasomotor effect and its mechanism in rat thoracic aorta.  Chin J Pharmacol Toxicol. 2005;  19 44-8
    PubMedGoogle Scholar
  • 21 Quan J, Du G. Protective effect of Astragalus membranaceus (Fisch.) Bge. and Hedysarum polybotrys Hand.-Mazz. on experimental model of cerebral ischemia in rats.  China J Chin Mater Med. 1998;  23 371-3
    PubMedGoogle Scholar
  • 22 Chen L X, Liao J Z, Guo W Q. Effects of Astragalus membranaceus on left ventricular function and oxygen free radical in acute myocardial infarction patients and mechanism of its cardiotonic action.  Chin J Integr Trad Western Med. 1995;  15 141-3
    PubMedGoogle Scholar
  • 23 Li S Q, Yuan R X, Gao H, Wang Y Q. Clinical observation on treatment of ischemic heart disease with Astragalus membranaceus .  Chin J Integr Trad Western Med. 1995;  15 77-80
    PubMedGoogle Scholar
  • 24 Zhou S N, Shao W, Zhang W G, Lu X Y, Yu S Q. Clinical study of Astragalus membranaceus injection on protecting myocardial ischemia-reperfusion injury.  Chin J Integr Trad Western Med. 2000;  7 168-70
    PubMedGoogle Scholar

Wei-Dong Zhang

Department of Natural Medicinal Chemistry

School of Pharmacy

Second Military Medical University

325 Guohe Rd.

Shanghai 200433

People’s Republic of China

Phone: +86-21-2507-0386

Fax: +86-21-2507-0386

Email: WDZhangY@hotmail.com

      >